MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-14-2025
Titan Pharmaceuticals DSO Ratio 2011-2026 | TTNP
Annual DSO Ratio Titan Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81.3 | 48.5 | 119 | - | 100 | 113 | 110 | 86.9 | 920 | 397 | 168 | 238 | 334 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 920 | 48.5 | 226 |
Quarterly DSO Ratio Titan Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 399 | 9.34 | 20.5 | - | 72 | 97 | 78.4 | - | 63.6 | 51.4 | 85.8 | - | 79.2 | 64.6 | 53.6 | 53.6 | 95.7 | 180 | 132 | 128 | 96.1 | 59.4 | 77.3 | 102 | 148 | 77 | 4.17 K | 9.35 K | 12.6 K | 21.8 | - | - | - | 506 | 410 | 397 | 397 | 397 | 440 | 483 | 200 | 200 | 83.5 | 130 | 345 | 312 | 301 | 240 | 335 | 488 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 K | 9.34 | 773 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.02 | -0.98 % | $ 189 M |  Israel |
 |
Happiness Biotech Group Limited
HAPP
|
29 | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
559 | $ 1.42 | - | $ 166 M |  USA |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
1.73 | - | - | $ 2.17 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 51.48 | -0.23 % | $ 4.63 B |  Schweiz |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 29.6 | 3.64 % | $ 1.97 B | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
2.16 K | - | - | $ 13.1 M | Canada |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | USA |
 |
Anika Therapeutics
ANIK
|
76.5 | $ 14.57 | -0.21 % | $ 209 M | USA |
 |
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.91 | -5.52 % | $ 4.79 M | Israel |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 22.79 | 5.8 % | $ 2.9 B | USA |